βWe are about to enter the era of interventional psychiatry, transforming the field of psychiatry.β β Tom Insel, former NIMH Director, at a recent psychedelic science conference.
We have invested in many of these new modalities: transcranial focused ultrasound (Sanmai), minimally invasive deep brain stimulation and vagus nerve stimulation (Neurobionics), brain-computer-interfaces (Neuralink), auditory dream engineering (Dust), psychedelic-assisted therapy (atai/Lilly), and real-world-data collection for all (Osmind).
Insel also co-authored a Nature paper with Osmind defining the field.
Interventional psychiatry companies:
β’ tFUS: Sanm.ai/technology
β’ Endovascular DBS: Neurobionics.io
β’ BCI: Neuralink.com
β’ Dream engineering: DUST.systems
β’ Psychedelics: ataibeckley.com
P.S. Underfunded: βFrom 2002-2013, the NIMH did not receive any funding applications for psychedelics. It was all funded and legitimized by philanthropy.β
P.S.S. Needed: βThe World Health Organization (WHO) predicts that without significant changes, mental illness will cost the world economy $16t by 2030, making it the largest disease burden globally." β UBS: flic.kr/p/2jcRcoS
We need significant changes.
Leave a Reply